
Needlestick and Splash Exposure Flow Chart Clinical Practice Guidelines

If ANY employee (including resident/fellow/attending) experiences a needlestick or splash exposure ANY time of day/night, they need to **page 708 643-0833** (**in the event the paging system is down, see bottom of page 6)

- 1) Employee Health working hours are weekdays 7:30a.m.-4:00p.m. All other times are "off hours".
- 2) Nursing Supervisor all other times. When Nursing Supervisor receives this page, the Nursing Supervisor will:




Blood/Body Fluid

Exposure Policy.

- 1) Injured employee name
- 2) Time of injury
- 3) Source patient when known

Needlestick and Splash Exposure Flow Chart Clinical Practice Guidelines



Needlestick and Splash Exposure Flow Chart Clinical Practice Guidelines HIV POSITIVE SOURCE (For ED/Employee Health)

For HIV Positive Source, ED Physician/Employee Health will contact:

- 1) Admitting attending physician of source patient
- 2) Infectious Disease Consult Pager 708 643-4480

At time of initial evaluation in ED/Employee Health, employee should be scheduled for follow up in Infectious Disease (ID) Clinic within 7 days. Contact ID Clinic at 708-216-5024 or708-216-3135.

ED/Employee Health will obtain baseline studies of HIV antigen and antibody (HIVABG), CMP (stat), CBC with diff (and beta HCG if female during childbearing years).

╁

Post Exposure Prophylaxis (PEP) should be started **as soon as possible** but less than 72 hours post exposure and continue for 28 days. If exposure is greater than 72 hours then ID Fellow will determine if PEP should still be administered.

ED/Employee Health will obtain height and weight of the employee and calculate Creatinine Clearance in order to determine the appropriate tenofovir/emtricitabine dose. (Epic can automatically calculate CrCl.)

ł

Treatment Regimen: Unless exposure is judged as NO RISK by Employee Health/ED (in which case no PEP is needed) or Source patient known to have antiretroviral resistance (in which case recommendations for PEP should be tailored), Infectious Disease Fellow will proceed with the following treatment and may alter the treatment based on assessment of source patient's


HIV Conversion after HIV positive exposure risk			
Exposure	Risk		
Needle stick	0.3% (1/300 chance)		
Mucous Membrane Exposure	0.1% (1/1000 chance)		
Small amount of blood splash to intact skin	No risk		
Urine (not bloody) splash to skin or mucous membranes	No risk		

Needlestick and Splash Exposure Flow Chart **Clinical Practice Guidelines HIV POSITIVE SOURCE (For Infectious Disease Fellow)**


	PEP	Renal	Medications		
	Choice	Function			
	KIT A	CrCl ≥ 50	tenofovir 300mg/emtricitabine 200mg 1 tab		
			by mouth ONCE daily,		
			plus		
			raltegravir 400mg 1 tab by mouth TWICE daily		
	KIT B	CrCl 30-49	tenofovir 300mg/emtricitabine 200mg 1 tab		
			by mouth q 48 hours,		
			plus		
			raltegravir 400mg 1 tab by mouth TWICE daily		
if CrCl < 30 an alternative regimen will be chosen without tenofovir					
			•		
PEP kits	containin	g a 7 day sup	ply of tenofovir/emtricitabine and raltegravir are		
			armacy. The remaining 21 days of medication sho	buld	
			nacy with a prescription and prescription program		
			Employee and exposure is work related.		
	20 yolu me				
			L		
If a PEP regim	nen differs	from tenofo	vir/emtricitabine/raltegravir, then a prescription s	hould	
			with the prescription program form. If you are a		
			posure is work related, a prescription (RX) can be		
the Loyola Outpatient Pharmacy during operating hours. Monday-Friday 8am-4:30pm closed					
1-1:45 pm. After hours, RX may be filled through the Loyola inpatient pharmacy or an outside					
retail pharmacy.					
L					
▼					
Employee Health/ID will obtain repeat CBC with diff and CMP 2 weeks after starting HIV					
prophylaxis.					
			¥		
Employee Health/ID will obtain HIV antigen and antibody (HIVABG) at 6 weeks and 4 months					
post exposure.					
\downarrow					
Υ					

Any communication with injured employee can be documented as a brief clinical update note in EPIC.

Needlestick and Splash Exposure Flow Chart Page 5 Clinical Practice Guidelines HEPATITIS B SURFACE ANTIGEN POSITIVE SOURCE (For ED/Employee Health)



HEPATITIS C POSITIVE SOURCE (For ED/Employee Health)



Hepatitis C conversion after Hepatitis C exposure risk		
Needle stick	1.8% (~2/100 chance)	
Mucous Membrane Exposure	Risk not quantified	

Employee Health will draw the following labs at 4-6 weeks, and 4-6 months post exposure: Hepatitis C antibody (HCVAB) and HCV-RNA. If patient source HIV <u>AND</u> Hep C positive, Employee Health will obtain additional HIVABG and Hep C antibody at 12 months post exposure. These employees/students will be seen in the ID clinic.

Employees with a positive antibody to HCV and/or positive HCV-RNA will be referred for prompt evaluation by a Hepatologist. There is some limited evidence that treating patients in the acute phase of HCV infection has benefits.

UNKNOWN SOURCE (For ED/EmployeeHealth)

For Unknown HIV:

ED Physician/Employee Health assess circumstance of exposure and contacts ID fellow as needed. The severity of exposure and epidemiologic risk will need to be assessed on a case by case basis.

If exposed employee meets risk criteria to warrant exposed person's treatment, then the PEP regimen should be as per the known HIV source on page 3 of flow chart.

For Unknown Hepatitis (Hep B and Hep C):

ED Physician/Employee Health assesses circumstance of exposure.

If exposed employee meets risk criteria to warrant exposed person's treatment, then the PEP regimen should be as per the known Hep B/Hep C source on page 5 of flow chart.

**In the event the paging system is down and you cannot page 708 643-0833

- 1) During weekday working hours 7:30a.m.-4:00p.m., call 6-2312
- 2) During weekends and off hours, call 6-0333 and state "nursing supervisor" to use Vocera to contact nursing supervisor